H. Lundbeck A/S (0ND5.IL)

32,86 -0,28 (-0,86%) Ab 02:09PM BST. Markt geöffnet.

H. Lundbeck A/S

Ottiliavej 9
Valby 2500
Denmark
45 36 30 13 11
https://www.lundbeck.com

Sektor(en): Healthcare
Branche: Drug Manufacturers - Specialty & Generic
Vollzeitmitarbeiter: 5.600

Leitende Angestellte

Name	Titel	Zahlen	Ausgeübt	Geburtsjahr
Mr. Joerg Hornstein	CFO & Exec. VP of Corp. Functions	3,4M	N/A	1977
Mr. Jacob Tolstrup	Exec. VP of Commercial Operations	8,2M	N/A	1972
Mr. Lars Bang	Exec. VP of Product Devel. & Supply	7,7M	N/A	1962
Dr. Per Johan Luthman	Exec. VP of R&D	8,6M	N/A	1959
Mr. Charl van Zyl	Pres & CEO	N/A	N/A	1967
Dr. Tarek Samad Ph.D.	Sr. VP & Head of Research	N/A	N/A	N/A
Mr. Palle Holm Olesen	Chief Specialist & VP of Investor Relations	N/A	N/A	N/A
Ms. Elise Hauge	Exec. VP of People & Communication	N/A	N/A	1967
Mr. Ole Chrintz	Sr. VP of International Markets	N/A	N/A	1958
Mr. Keld Flintholm Jorgensen	Exec. VP of Corp. Strategy & Bus. Devel.	N/A	N/A	1971

Die Beträge haben den Stand 31. Dezember 2022 und Kompensationswerte gelten für das letzte Geschäftsjahr bis zu diesem Datum. Der Lohn umfasst Gehalt, Boni usw. „Ausgeübt“ entspricht dem Wert von Optionen, die im Lauf des Geschäftsjahrs ausgeübt werden. Währung in DKK.

Beschreibung

H. Lundbeck A/S, a biopharmaceutical company, engages in the research, development, production, and sale of pharmaceuticals for the treatment of psychiatric and neurological disorders in Europe, United States, and internationally. The company's principal products include Abilify Maintena for schizophrenia; Brintellix/Trintellix to treat depression; Northera for the treatment of symptomatic neurogenic orthostatic hypotension; Vyepti for migraine prevention; and Rexulti/Rxulti to treat depression/schizophrenia. It also provides Azilect for treating Parkinson's disease; Cipralex/Lexapro for depression; Ebixa to treat Alzheimer's disease; Onfi for Lennox-Gastaut syndrome; Sabril for treating epilepsy; and Xenazine for chorea associated with Huntington's disease, as well as other products. The company sells its products primarily to distributors of pharmaceuticals, pharmacies, and hospitals. It has a partnership collaboration with Otsuka Pharmaceuticals Co., Ltd.; and collaboration with FeetMe focusing on the use of sensor shoe soles. H. Lundbeck A/S also has a collaboration with Alloy Therapeutics, Inc. for the discovery of novel biologics therapies. The company was founded in 1915 and is headquartered in Valby, Denmark.

Corporate Governance

H. Lundbeck A/Ss ISS Governance QualityScore, Stand 1. Oktober 2023, lautet 2. Die grundlegenden Scores sind Audit: 4, Vorstand: 3, Shareholderrechte: 9, Kompensation: 2.

Corporate-Governance-Bewertungen von Institutional Shareholder Services (ISS). Die Werte geben den Zehntelwert im Verhältnis zum Index oder zur Region an. Ein Zehntelwert von 1 zeigt geringeres Governance-Risiko, 10 höheres Governance-Risiko.